Health and Life Sciences at the Edge: Privacy Frameworks in Health and Life Sciences

The American Journal of Medicine noted that healthcare organizations, or HCOs, require a framework that preserves privacy and supports the kind of data collaboration that will make tomorrow’s scientific and clinical advances possible while still supporting improved patient outcomes and experiences. Establishing this framework is challenging. Can AI solutions meet those privacy requirements for healthcare and life science applications? This is the question host Hilary Kennedy posed to BeeKeeperAI’s CEO Michael Blum, MD and Intel’s Health and Life Sciences General Manager, Chris Gough.

“Even large health organizations do not have the diversity, quality, or amount of data required to create high-quality, generalizable AI,” said Blum. “The solution is a federated framework that allows each data steward to ensure the privacy of their data by keeping it in their protected cloud, while validating and training AI across all of those stewards.”

Gough agreed, saying, “If you can reduce the friction to accessing large, diverse, high-quality data sets – and use those data sets as part of the AI training step – then the algorithms that result will be more accurate for multiple populations.”

“Healthcare AI is projected to be a $46 billion dollar market. When you turn that into human impact, there’s a tremendous opportunity to improve the quality of care and reduce the cost of care,” said Blum. “But the challenge we see over-and-over again is that the algorithms don’t generalize across populations. Their accuracy and performance fall off dramatically. We have to get rapid access to much broader and much more diverse data sets.”

“We really have a supply and demand problem in healthcare,” Gough added. “AI will help the industry better target the scarce resources it has, allowing organizations to be less reactive and more proactive and predictive.”

To learn more about Michael Blum, MD, and Chris Gough:

Read the “Privacy-Preserving Data-Collaboration Methods that Accelerate Healthcare Innovation” white paper: https://www.intel.com/content/www/us/en/healthcare-it/resources/confidential-computing-whitepaper.html

Subscribe to this channel on Apple Podcasts, Spotify, or Google Podcasts to hear more from the Intel Internet of Things Group.

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More